CDER Eyes Prioritization, Timely Resolution Of Post-Marketing Safety Issues
Executive Summary
Now that it has a system in place to track post-marketing drug safety issues, FDA’s Center for Drug Evaluation and Research is turning its attention to setting standard timeframes for investigating and addressing such signals.